Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monoclonal Antibody 3F8 and Oral Etoposide for the Treatment of Neuroblastoma

Trial Profile

Monoclonal Antibody 3F8 and Oral Etoposide for the Treatment of Neuroblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2009

At a glance

  • Drugs Etoposide; Isotretinoin; Monoclonal antibody 3F8
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top